Design and Evaluation of Modified Release Dosage Form Containing Bupropion Hydrochloride

In the present investigation an attempt was made to reduce the frequency of dose administration, to improve the patient compliance by developing Modified release matrix tablet of Bupropion Hydrochloride (BPH). Bupropion has been approved by the Food and Drug Administration (FDA) for use in smoking cessation. Eleven batches of matrix tablets of BPH were developed by using direct compression technique and coated with Opadry white. Compressed tablets were evaluated for weight variation, hardness, friability, similarity factor (f2) and in vitro dissolution using paddle (USP type II) method. Drug excipients compatibility study was also performed using differential scanning calorimetry (DSC). All the formulations were compared with the innovator. Among the eleven formulations F11 batch shows comparative dissolution profile with the innovator.